1. Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients
- Author
-
Hulya Hacisahinogullari, Gulsah Yenidunya Yalin, Ozlem Soyluk Selcukbiricik, Nurdan Gul, Bilge Bilgic, Ayse Kubat Uzum, Refik Tanakol, and Ferihan Aral
- Subjects
Cabergoline ,Human Growth Hormone ,Endocrinology, Diabetes and Metabolism ,Biochemistry (medical) ,Clinical Biochemistry ,General Medicine ,Biochemistry ,Prolactin ,Endocrinology ,Acromegaly ,Humans ,Ergolines ,Insulin-Like Growth Factor I ,Retrospective Studies - Abstract
The aim of this study was to evaluate the efficacy of cabergoline in normalizing plasma IGF-I levels in acromegaly patients with elevated IGF-I levels after surgery and/or SRL therapy. Acromegaly patients (n: 143) were evaluated retrospectively. Patients with elevated IGF-I levels after surgery and/or SRLs therapy and a fixed dose of SRLs treatment for the last six months with no history of radiotherapy in the last three years were included in the study (n: 12). Previous treatment regimens, baseline PRL and IGF-I levels (ULNR), sella MRI, and immunohistochemical findings were evaluated. Cabergoline was used as an add on (n: 11) or single medical treatment (n: 1). The median duration of treatment with SRL alone was 12 months (range 6–48 months). The mean IGF-I value before cabergoline therapy was 1.45±0.4 ULNR. The mean cabergoline dose and duration of treatment were 1.55±0.75 mg/week and 9±6.3 months, respectively. IGF-I normalization was only achieved in patients with serum IGF-I concentration
- Published
- 2022